<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-191 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-191</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-191</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.016</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e191.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e191.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>East Asian never-smokers (Shanghai cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Lung adenocarcinomas from East Asian (Chinese) never-smokers — Shanghai Cancer Hospital cohort</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Surgical series of 52 resected lung adenocarcinomas from Chinese never-smokers showing a very high prevalence of EGFR kinase-domain mutations, with most mutations being exon 19 deletions or L858R.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>52 resected lung adenocarcinomas from never-smokers (all Chinese) collected consecutively at Shanghai Cancer Hospital, Fudan University (January 2008–June 2009).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Chinese / East Asian</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>78.8% (41 of 52; 95% CI, 0.6580 to 0.8792)</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Exon 19 deletions: 21 tumors; L858R (exon 21) missense: 18 tumors; exon 20 insertion: 1 tumor; double mutation G719S (exon 18) + L861Q (exon 21): 1 tumor; no T790M mutations detected.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Never-smokers only (defined as <100 cigarettes lifetime).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Study restricted to never-smokers; authors note EGFR mutations are enriched in never-smokers in general and that likelihood of EGFR mutations decreases with increasing pack-years (cited literature). Within this cohort, EGFR mutations occurred in 82.9% (34/41) of female tumors vs 63.6% (7/11) of male tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No cohort-specific environmental exposures reported; paper references environmental risk factors for lung cancer in never-smokers in the introduction but does not provide data on exposures (eg, secondhand smoke, cooking fumes) for this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>No cohort-specific germline risk variants reported. The paper notes T790M can rarely be a germline variant (cited) but none were detected in this series.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>No direct internal comparator cohort; authors frame results against previously published data in East Asian and non-Asian (including white) populations (cited literature) indicating higher EGFR mutation prevalence in East Asian never-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors do not offer a definitive mechanistic explanation for higher EGFR mutation prevalence in East Asian never-smokers; they discuss that genetic background and lower tobacco exposure likely contribute and note differences in the prevalence of other mutations (eg, lower KRAS and LKB1 in East Asians) as consistent with ancestry-related molecular differences.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Predominantly female (41/52), mean age ≈59 years, adenocarcinoma histology, stages I–IV included; EGFR-mutant tumors mainly exon 19 deletions and L858R; PIK3CA mutations (4 cases, 7.7%) co-occurred with EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Single-institution surgical series (selection for resectable disease), small sample size (n=52), female-dominant cohort, requirement for ≥70% tumor cellularity — these sampling/selection constraints could influence observed frequencies relative to unselected populations.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Cohort drawn from Shanghai, China; paper discusses broader East Asian versus Caucasian differences but provides no within-China geographic stratification.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e191.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e191.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>IPASS (Pan-Asian Study)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Iressa Pan-Asia Study (IPASS): Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase III trial in East Asian patients with pulmonary adenocarcinoma who were never-smokers or former light-smokers, demonstrating that EGFR-mutant patients derive greater progression-free survival benefit from gefitinib than chemotherapy and that response rates are much higher in EGFR-mutant cases.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Previously untreated East Asian patients with advanced pulmonary adenocarcinomas who were never-smokers or former light-smokers (as described in this paper); the current paper does not give IPASS sample size.</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>East Asian</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Never-smokers or former light-smokers (stopped ≥15 years previously and ≤10 pack-years) — the IPASS inclusion described in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>IPASS results (cited) support that EGFR-mutant tumors predict benefit from gefitinib in East Asian never/light smokers; implies enrichment of EGFR mutations in that clinical group.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Within-trial comparison of gefitinib vs carboplatin-paclitaxel in East Asian never/light smokers; subgroup analysis by EGFR-mutation status showed differing benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Overall radiographic response rate to gefitinib in IPASS cohort was 43%; in patients with known EGFR mutations the response rate was 71.2% (numbers reported in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Pan-Asian (East Asia) trial population.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e191.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e191.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pack-years association (Pham et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced study reporting an inverse relationship between cumulative tobacco exposure (pack-years) and the likelihood of finding activating EGFR exon 19 or 21 mutations in lung adenocarcinoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Focus on EGFR exons 19 and 21 (implied by title and text).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Addresses full spectrum of cigarette-smoking history (pack-years) and association with EGFR mutation probability.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Reported that the likelihood of EGFR mutations decreases as the number of pack-years increases.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Implicates tobacco exposure as reducing prevalence of EGFR-activating mutations (i.e., smoking-related mutational spectra differ).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e191.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e191.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS/EGFR reversed rates (Wu et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced work describing that mutation frequencies of KRAS and EGFR in lung adenocarcinoma in Taiwan differ from other reports (i.e., 'reversed' rates), providing evidence for geographic/ethnic variation in oncogene mutation prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Taiwanese lung adenocarcinoma patients (details not provided in the current paper).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Taiwanese / East Asian</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Implied comparison between Taiwan (East Asian) and other populations showing reversed KRAS vs EGFR frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Taiwan-specific data suggesting regional/ethnic variation in mutation spectra.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e191.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e191.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>LKB1 ethnicity difference (Koivunen et al.)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced study showing that LKB1 tumor-suppressor mutations are common in Caucasian lung cancer patients but rare in Asian patients, illustrating ancestry-associated differences in mutation prevalence across populations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Comparison between Caucasian and Asian lung cancer patients (Caucasian higher LKB1 mutation frequency).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Direct comparison reported between Caucasian and Asian tumors for LKB1 mutation prevalence.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Caucasian vs Asian differences highlighted.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <em>(Rating: 2)</em></li>
                <li>Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications <em>(Rating: 2)</em></li>
                <li>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients <em>(Rating: 2)</em></li>
                <li>Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>